ArticleBMJ case reports2020

Glecaprevir/pibrentasvir+sofosbuvir: an optimal retreatment strategy in the setting of HCV NS5A resistance.

Arshia Alimohammadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.